Literature DB >> 16783294

[Effectiveness of oral administration of Lactobacillus paracasei subsp. paracasei F19 in association with vaginal suppositories of Lactobacillus acidofilus in the treatment of vaginosis and in the prevention of recurrent vaginitis].

A Delia1, G Morgante, G Rago, M C Musacchio, F Petraglia, V De Leo.   

Abstract

AIM: The aim of this paper was to estimate the effectiveness of the contemporary oral administration of Lactobacilllus paracasei subsp paracasei F19 in association with vaginal suppositories containing Lactobacilllus acidofilus in the treatment of bacterial vaginosis and in the prevention of recurrent vaginitis.
METHODS: We have recruited 60 women in good health, aged between 18 and 40 years with suspect or confirmed diagnosis of bacterial vaginosis. The women were randomized in 2 groups: Group A treated with vaginal suppositories containing Lactobacillus acidofilus (Calagin, SIFFRA, Florence); Group B treated with the same vaginal suppositories + probiotic containing Lactobacilllus paracasei subsp paracasei F 19 for oral administration (Gene-filus F19, SIFFRA, Florence). The patients were examined at the end of therapy (3 months) and then after 3 months from the end of treatment.
RESULTS: In both groups at end of therapy there was a significant reduction of vaginal pH, an improvement of sniff test and of the subjective symptomatology after 3 months of treatment which still decreased during follow-up (3 months). In Group B there was a meaningful reduction of vaginal pH and of sniff test at the end of therapy and a maintenance of positive effect also after 3 months.
CONCLUSIONS: The results obtained in this study show that the therapy with vaginal Lactobacillus in the treatment of bacterial vaginosis is successful. The association of oral administration is useful to balance the vaginal environment with the intestinal microflora with improvement of long-term results. The use of probiotics was determinant in the treatment of a pathology like bacterial vaginosis and as an alternative to the conventional local antibiotic therapies.

Entities:  

Mesh:

Year:  2006        PMID: 16783294

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  6 in total

1.  NATURAL ANTIMICROBIALS AND THEIR ROLE IN VAGINAL HEALTH: A SHORT REVIEW.

Authors:  S E Dover; A A Aroutcheva; S Faro; M L Chikindas
Journal:  Int J Probiotics Prebiotics       Date:  2008

2.  Polyethylene glycol-based hydrogels for controlled release of the antimicrobial subtilosin for prophylaxis of bacterial vaginosis.

Authors:  Sujata Sundara Rajan; Veronica L Cavera; Xiaoping Zhang; Yashveer Singh; Michael L Chikindas; Patrick J Sinko
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

3.  Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment.

Authors:  Sujata Sundara Rajan; Yevgeniy Turovskiy; Yashveer Singh; Michael L Chikindas; Patrick J Sinko
Journal:  J Control Release       Date:  2014-09-16       Impact factor: 9.776

4.  Bacterial vaginosis: Etiology and modalities of treatment-A brief note.

Authors:  Nikhil Kumar; Beauty Behera; Sai S Sagiri; Kunal Pal; Sirsendu S Ray; Saroj Roy
Journal:  J Pharm Bioallied Sci       Date:  2011-10

5.  Efficacy and safety of a vaginal medicinal product containing three strains of probiotic bacteria: a multicenter, randomized, double-blind, and placebo-controlled trial.

Authors:  Anna Tomusiak; Magdalena Strus; Piotr B Heczko; Paweł Adamski; Grzegorz Stefański; Aleksandra Mikołajczyk-Cichońska; Magdalena Suda-Szczurek
Journal:  Drug Des Devel Ther       Date:  2015-09-25       Impact factor: 4.162

6.  Supplementation of standard antibiotic therapy with oral probiotics for bacterial vaginosis and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Piotr B Heczko; Anna Tomusiak; Paweł Adamski; Artur J Jakimiuk; Grzegorz Stefański; Aleksandra Mikołajczyk-Cichońska; Magdalena Suda-Szczurek; Magdalena Strus
Journal:  BMC Womens Health       Date:  2015-12-03       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.